Assembly Biosciences Inc (ASMB) FinancialsASMBFinancialAssembly Biosciences Inc

Evaluating the bottom line, Assembly Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -47.44%, while the net margin is -28.84%. These profitability ratios, combined with a Return on Equity (ROE) of -0.03%, provide a clear picture of how effectively ASMB converts its operational activities into shareholder value.

In the context of the broader market, ASMB competes directly with industry leaders such as GYRE and CTMX. With a market capitalization of $670.88M, it holds a significant position in the sector. When comparing efficiency, ASMB's gross margin of 100.00% stands against GYRE's 92.41% and CTMX's 100.00%. Such benchmarking helps identify whether Assembly Biosciences Inc is trading at a premium or discount relative to its financial performance.

Assembly Biosciences has shown significant revenue growth, with a 153.5% increase year-over-year, reaching $72.3 million. However, it continues to report negative net income, with the latest EPS at -0.20, indicating ongoing losses despite revenue growth.